Butterfly Network, Inc. Reports 2020 Financial Results | Business & Finance
GUILFORD, Conn. & NEW YORK--(BUSINESS WIRE)--Mar 29, 2021--Butterfly Network, Inc. (NYSE: BFLY) (“Butterfly” or the “Company”), a digital health company...
Reports
Frequency Therapeutics Provides Business Updates and Reports Fourth Quarter and Full Year 2020 Financial Results
BloombergBig Oil’s Secret World of Trading(Bloomberg Markets) -- It was a bleak moment for the oil industry. U.S. shale companies...
AbCellera Reports Full Year 2020 Business Results
Total revenue of $233 million1 in 2020, up 1,908% year-over-yearTotal revenue from research fees of $20 million, up 71% year-over-yearTotal...
GenScript Biotech Reports Full Year 2020 Financial Results and Business Results
Reported a revenue of approximately USD 390 million, a 42.9% YoY increase, and a gross profit of USD 260 million,...
OSE Immunotherapeutics Reports 2020 Financial Results and Provides Business Update
Major expansion of clinical portfolio including initiation of clinical trials with Tedopi® in ovarian cancer, OSE-127/S95011 in ulcerative colitis, FR104...
Panbela Provides Business Update and Reports Q4 and FY 2020 Financial Results
MINNEAPOLIS, March 25, 2021 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics...
Phio Pharmaceuticals Reports 2020 Year End Financial Results and Provides Business Update
MARLBOROUGH, Mass., March 25, 2021 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of...
Inpixon Reports 2020 Financial Results and Provides Business Update
PALO ALTO, Calif., March 25, 2021 /PRNewswire/ -- Inpixon (Nasdaq: INPX), the Indoor Intelligence™ company, today provided a business update...
Ayala Pharmaceuticals Reports Full Year 2020 Financial Results and Provides Business Update
- Completed $25 Million Strategic Financing; Extending Cash Runway into 2023- Accelerated Development of AL102 Desmoid Tumor Program into Phase...
Immunocore Provides Business Update and Reports Full Year 2020 Financial Results
Immunocore Provides Business Update and Reports Full Year 2020 Financial Results Breakthrough Therapy Designation granted by the FDA for tebentafusp...
Evolus Reports Fourth Quarter and Full Year 2020 Results and Provides Business Update
Q4 2020 Net Revenue $20.6 Million, Highest Net Revenue Quarter Since Launch of Jeuveau®Pro Forma Cash Position of $57 Million...
Celyad Oncology Reports Full Year 2020 Financial Results and Recent Business Highlights
No safety concerns or evidence of Graft-versus-Host disease reported from first dose cohort of Phase 1 dose-escalation IMMUNICY-1 trial for...
Sana Biotechnology Reports Fourth Quarter and 2020 Financial Results and Business Updates
Expects to present data at multiple scientific conferences in 20212020 year-end cash position of $412 millionFurther strengthened cash position with...
Kronos Bio Reports Recent Business Progress and Fourth Quarter and Full Year 2020 Financial Results
Positive End-of-Phase 2 meeting with the FDA for entospletinib in newly diagnosed NPM1-mutated acute myeloid leukemiaFirst patient dosed in Phase...
SELLAS Life Sciences Reports Full Year 2020 Financial Results and Provides Business Update
Entered into Exclusive License Agreement, with $7.5 Million Upfront License Fee and Potential to Receive up to an Additional $194.5...
IDEAYA Biosciences, Inc. Reports Fourth Quarter 2020 Financial Results and Provides Business Update
- Initiated Phase 1 clinical trial for IDE397, a potential best-in-class MAT2A inhibitor for patients having tumors with MTAP-deletion- Planning...
Newtek Business Services Corp. Reports Full Year 2020 Financial Results
BOCA RATON, Fla., March 22, 2021 (GLOBE NEWSWIRE) -- Newtek Business Services Corp. (“Newtek” or the “Company”) (Nasdaq: NEWT), an...
9 Meters Biopharma Provides Business Update and Reports Financial Results for the Fourth Quarter and Full Year 2020
FDA Type C meeting communications support plans to initiate Phase 2 in Q2 with NM-002 for short bowel syndrome (SBS)...
